Peptide Vaccine

BIOLOGICAL10 trials

Sponsors

Chiba University, Ahmad Tarhini, H. Lee Moffitt Cancer Center and Research Institute, Kinki University, University Hospital Tuebingen

Conditions

ALK Fusion Protein ExpressionAdvanced Renal Cell CancerAdvanced esophageal squamous cell carcinoma patietns treated with standart therapy includingn surgery, chemotherapy and radiotherapy, and all these treatments were failed.Chronic Kidney Disease, Stage 4Chronic Kidney Disease, Stage 5EBV-Related Lymphoproliferative DisorderEBV-Related Malignant NeoplasmGastric Cancer

Phase 1

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

CompletedNCT00471471

Ahmad TarhiniIntraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)

Start: 2008-10-31End: 2011-12-31Updated: 2017-06-22

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

CompletedNCT00845611

Kinki UniversityGastric Cancer

Start: 2008-09-30End: 2010-09-30Updated: 2012-04-06

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

University Hospital TuebingenAdvanced Renal Cell Cancer, Renal Cell Cancer

Start: 2005-05-31End: 2018-06-30Updated: 2017-08-17

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

University Hospital TuebingenRecurrent Prostate Cancer

Start: 2004-04-30End: 2017-10-31Updated: 2017-08-17

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

RecruitingNCT05950139

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsALK Fusion Protein Expression, NSCLC Stage IV

Start: 2024-05-13End: 2029-07-31Target: 12Updated: 2025-09-23

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

SuspendedNCT06741072

Ohio State University Comprehensive Cancer CenterChronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder +2

Start: 2026-03-01End: 2027-12-31Target: 55Updated: 2026-01-08

Phase 2

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

WithdrawnNCT02754362

NYU Langone HealthGlioblastoma, Glioma

Start: 2016-11-30End: 2019-06-30Updated: 2020-01-13

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

CompletedNCT02802943

University Hospital TuebingenLeukemia, Chronic Lymphatic

Start: 2016-10-05End: 2022-11-18Target: 56Updated: 2022-11-28

Unknown Phase

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

CompletedNCT00694551

H. Lee Moffitt Cancer Center and Research InstituteProstate Cancer

Start: 2008-12-02End: 2018-12-06Updated: 2019-10-04

Phase I clinical trial of newly developed antigen peptide vaccine for advanced esophageal cancer

Active, not recruitingJPRN-UMIN000004662

Chiba UniversityAdvanced esophageal squamous cell carcinoma patietns treated with standart therapy includingn surgery, chemotherapy and radiotherapy, and all these treatments were failed.

Start: 2010-01-01Target: 5Updated: 2025-07-18

Related Papers

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

Frontiers in Immunology2024-11-262 citations

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Frontiers in Oncology2024-03-2810 citations

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia

Frontiers in Immunology2021-07-0839 citations

Definition and Characterization of a Peptide Warehouse for the Patient-Individualized Peptide Vaccination Study (iVAC-L-CLL01) after First Line Therapy of CLL

Blood2017-12-073 citations

Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.

2017-10-0417 citations

Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer.

2013-04-2435 citations